Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medpace Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medpace Holdings's regulatory disclosures and financial reporting.
Medpace Holdings, Inc. director Robert O. Kraft exercised restricted stock units into common shares as part of his equity compensation. On June 30, he converted 33 restricted stock units into 33 shares of common stock at a stated price of $0.0000 per share. After this transaction, he directly holds 955 common shares and 64 remaining restricted stock units. These units come from a November 28, 2025 grant of 130 restricted stock units scheduled to vest in four approximately equal installments through December 31, 2026.
Medpace Holdings director Brian T. Carley exercised 36 restricted stock units into common stock on June 30, 2026. Following the transaction, he holds 32,825 shares of common stock and 71 remaining restricted stock units. The RSUs come from a 143-unit grant made on November 28, 2025.
Medpace Holdings, Inc. executive Brad W. Hansman, Exec. VP, Operations, filed an initial ownership report showing his equity position in the company. He directly holds 697 shares of common stock, reflecting his current direct stake.
He also holds an employee stock option for 10,000 shares of Medpace common stock at an exercise price of $410.54 per share, expiring on April 24, 2033, which vests in full on April 24, 2031, subject to continued employment. In addition, he has restricted stock units covering 5,000 shares that vest in full on August 5, 2029 and 500 shares that vest in full on April 24, 2031, each unit representing a contingent right to receive one share of MEDP common stock.
Medpace Holdings, Inc. has appointed Brad W. Hansman, age 43, as Executive Vice President, Operations effective June 1, 2026. In this role he will perform the functions of principal operating officer alongside existing Executive Vice President, Operations, Susan E. Burwig.
Hansman has been with Medpace since 2011, progressing through finance and key operational leadership roles overseeing study start-up, logistics, regulatory affairs, and medical writing. Earlier in his career he worked at Joseph Decosimo & Company and Macy’s and holds a BBA in Accounting and is a Certified Public Accountant (inactive).
In connection with the new role, Hansman will receive an annual base salary of $492,250, be eligible for the company’s short-term cash bonus plan based on a percentage of salary, and may receive awards under the long-term equity incentive plan at the Compensation Committee’s discretion. He has entered into Medpace’s standard indemnification agreement for executive officers.
Medpace Holdings, Inc. General Counsel & Corporate Secretary Stephen P. Ewald reported an exercise-and-sell transaction in company stock. He exercised options covering 16,349 shares of common stock at $138.87 per share and sold 16,349 shares in an open-market sale at $450.00 per share pursuant to a limit order placed during an open window period. Following these transactions, he holds 20,343 common shares directly.
Medpace Holdings, Inc. reported results of its 2026 annual stockholder meeting and related governance changes. Stockholders approved amendments to the Restated Certificate of Incorporation to remove supermajority voting requirements and to remove the prior limitation on stockholders calling special meetings, effective upon Delaware filing on May 18, 2026. The Board also amended the bylaws so one or more stockholders owning at least 25% of the Company’s voting power, and having held it continuously for one year, may request a special meeting, subject to notice and information requirements. Stockholders elected all director nominees, ratified Deloitte & Touche LLP as auditor for the year ending December 31, 2026, approved the advisory vote on executive compensation, and supported holding this advisory vote every year.
Medpace Holdings director Dani S. Zander received a stock option grant covering 1,110 shares of common stock at an exercise price of $415.27 per share. This is a compensation-related award, not an open-market trade, and represents a new derivative position for the director.
The option expires on May 15, 2033 and vests on the earlier of the day immediately before the first annual shareholder meeting following the grant date or the first anniversary of the grant date, as long as Zander continues serving on Medpace’s board through that vesting date.
Medpace Holdings, Inc. director Cornelius P. McCarthy III received a grant of stock options covering 1,110 shares of common stock at an exercise price of $415.2700 per share. These options expire on May 15, 2033 and are a compensation-related award, not an open-market purchase.
According to the footnote, the option vests on the earlier of the day immediately preceding the first annual shareholder meeting after the grant date or the first anniversary of the grant, subject to his continued service on the board. Following the reported transactions, he holds 10,324 shares of common stock directly.
Medpace Holdings, Inc. director Robert O. Kraft reported a new stock option award and his current share holdings. He received options to buy 1,110 shares of common stock at an exercise price of $415.27 per share, expiring on May 15, 2033. Following the award, he holds 922 shares of common stock directly. The option vests on the earlier of the day immediately before the first annual meeting after the grant date or the first anniversary of the grant date, subject to his continued service on the board.